Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
Forte Biosciences, Inc. (FBRX)
Company Research
Source: Business Wire
Additional data continues to support highly differentiated profile for FB102 in celiac disease DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation “FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study - Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital” at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland) on Friday September 12, 2025, further supporting the significant differentiation of FB102 in celiac disease.Highlights of the oral presentation include:FB102 demonstrated a decline in the TCR ?d density from baseline of 1.5 compared to an increase of 3.9 for placebo (p=0.0007)TCR ?d cells produce pro-inflammatory cytokines including IFN-? and TNF-a and upregulate activating receptors on epithelial c
Show less
Read more
Impact Snapshot
Event Time:
FBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBRX alerts
High impacting Forte Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
FBRX
News
- Forte Biosciences (NASDAQ:FBRX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Forte Biosciences (NASDAQ:FBRX) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Forte Biosciences (NASDAQ:FBRX) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.MarketBeat
- Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesBusiness Wire
- Forte Biosciences (NASDAQ:FBRX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
FBRX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form 10-Q
- FBRX's page on the SEC website